Preceden

News

KEY NEWS DEVELOPMENTS:

Product Related Announcements

Positive results for Facor 8 FC Fusion protein in Hemophilia A

10/31/2012

Special Call, Swedish Orphan Biovitrum AB- Special Call

10/31/2012

Reports Top Line Results of EMPOWER

01/04/2013

Sent FDA application for first long lasting factor 9 therapy for Hemophlia B

01/04/2013

Positive results phase 3 study of Peginterferon Beta -1a in Multiple Sclerosis

01/24/2013

Committee for CHMP issues positive opinion for Biogen’s TECFIDERA

03/22/2013

FDA approval of TECFIDERA as a First Line oral Treatment for Multiple sclerosis

03/27/2013

Canada approves TECFIDERA as a First-Line Oral Treatment for Multiple Sclerosis

04/09/2013

Lawsuit and Legal Issue

Knopp Neurosciences Files Lawsuit in fall out from termination of licensing deal

04/05/2013

M&A Transaction Closing

Completed the acquisition of reminaing 50% stake in TYSABRI from Elan Pharma LTD

04/02/2013

Strategic Alliances

Business Expansion - Opens NEW RTP FACILITY

11/29/2012

Phase 3 Data reinforce protection from Bleeding for hemophilia A and B patients

02/08/2013

Submit app for First Line Use Tysabri in Anti-JCV Antibody Negative MS Patients

02/08/2013

Elan Corporation announces restructuring of Tysabri in collaboration with Biogen

02/22/2013

FDA accepts license app for FIRST LONG LASTING FACTOR 9 Therapy for Hemophilia B

03/04/2013

Elan Corporation announced the closing of TYSABRI collaboration transcation

04/02/2013